They lower intracranial pressure
The prescribing information for all GLP-1 medications explicitly states that missed doses should not be compensated for by increasing subsequent doses
GLP-1s are primarily indicated for obesity and diabetes, two major global health challenges that continue to grow at alarming rates
Zepbound and Retatrutide do share the same baseline of gastrointestinal side effects (like nausea and constipation), however, because Retatrutide targets a third hormone (glucagon), it introduces a couple of side effects not seen with Zepbound, specifically related to heart rate and skin sensitivity
Confirm Endpoints as a trusted biopharma news source more like this The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO says July 27, 2026 MapLights schizophrenia drug dampens once-daily hopes despite Phase 2 win July 27, 2026 AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings July 27, 2026 ENDPOINTS CAREERS Scientist, Drug Discovery Data for AI/ML D
and disclaims any liability arising thereof
